ArticleNature communications2016
Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Bridging hydrogen-bond-stabilized polymeric coacervate core micelles for high-efficiency drug encapsulation and delivery.Nature communications · 2026Article
- Cascade Therapy of Periodontitis via Sequential Release of Ribosome-Targeting Antimicrobial Peptide and Irisin From a Multifunctional MOF-Based System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancements in Nanocarrier Delivery Systems for Photodynamic Therapy in Lung Cancer.International journal of nanomedicine · 2025Review
- Endoperoxide-enhanced self-assembled ROS producer as intracellular prodrugs for tumor chemotherapy and chemodynamic therapy.Exploration (Beijing, China) · 2024Article
- Combined ROS Sensitive PEG-PPS-PEG with Peptide Agonist for Effective Target Therapy in Mouse Model.International journal of nanomedicine · 2024Article
- Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer.Drug delivery · 2022Article
- Article
- [Research progress on the fluorescence resonance energy transfer-based polymer micelles as drug carriers].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022Review
- Dynamic covalent chemistry in live cells for organelle targeting and enhanced photodynamic action.Chemical science · 2022Article
- Improved Core Viscosity Achieved by PDLLAPharmaceutical research · 2022Article
- Structurally defined tandem-responsive nanoassemblies composed of dipeptide-based photosensitive derivatives and hypoxia-activated camptothecin prodrugs against primary and metastatic breast tumors.Acta pharmaceutica Sinica. B · 2022Article
- Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- FRET Ratiometric Nanoprobes for Nanoparticle Monitoring.Biosensors · 2021Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- A modular approach toward producing nanotherapeutics targeting the innate immune system.Science advances · 2021Article
- Like dissolves like: A first-principles theory for predicting liquid miscibility and mixture dielectric constant.Science advances · 2021Article
- Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity.International journal of nanomedicine · 2021Article
- Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.Theranostics · 2021Article
- pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics.Communications biology · 2020Article
- Imaging-assisted anticancer nanotherapy.Theranostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug-carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, a large number of currently available nanocarriers are self-assembled nanoparticles whose drug-loading stability is critically affected by the in vivo environment. Here we used in vivo FRET imaging to systematically investigate how drug-carrier compatibility affects drug release in a tumour mouse model. We found the drug's hydrophobicity and miscibility with the nanoparticles are two independent key parameters that determine its accumulation in the tumour. Next, we applied these findings to improve chemotherapeutic delivery by augmenting the parent drug's compatibility; as a result, we achieved better antitumour efficacy. Our results help elucidate nanomedicines' in vivo fate and provide guidelines for efficient drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.